Podcasts about Oncology

Klash With Kenzie takes a dark turn. Chicago’s best morning radio show now has a podcast! Don’t forget to rate, review, and subscribe wherever you listen to podcasts and remember that the conversation always lives on the Q101 Facebook page. Brian & Kenzie are live every morning from 6a-10a on Q101. Subscribe to our channel HERE: https://www.youtube.com/@Q101 Like Q101 on Facebook HERE: https://www.facebook.com/q101chicago Follow Q101 on Twitter HERE: https://twitter.com/Q101Chicago Follow Q101 on Instagram HERE: https://www.instagram.com/q101chicago/?hl=en Follow Q101 on TikTok HERE: https://www.tiktok.com/@q101chicago?lang=enSee omnystudio.com/listener for privacy information.

Host: Mindy McCulley, MS, Extension Specialist for Instructional Support, Family and Consumer Sciences Extension, University of Kentucky  Guests: Nathan Vanderford, PhD Director, Appalachian Career Training in Oncology Program, Markey Cancer Center, Kameron Jackson and Matthew Sanders, ACTION Program student participants Cancer Conversations Episode 72 Welcome to Cancer Conversations on Talking FACS with host Mindy McCulley. In this episode we hear from Dr. Nathan Vanderford, director of the NIH-funded ACTION (Appalachian Career Training in Oncology) program, and students Kameron Jackson and Matthew Sanders about how the program engages Eastern Kentucky high school and undergraduate students in cancer education, lab research, clinical shadowing, mentorship, and community outreach. Topics covered include student experiences in research labs and mentorship, the program's recruitment across the 54 Appalachian counties, and a unique writing project that produced four books of personal and realistic fictional stories about cancer in Eastern Kentucky. Kameron and Matthew describe how writing helped them process family history, spark conversations about cancer, and build communication skills alongside scientific training. Key takeaways: ACTION provides hands‑on research and outreach opportunities that change career trajectories, creative writing can open difficult conversations about cancer in communities, and the program aims to broaden access across the region. Find the students' stories and the full book linked in the episode show notes and visit Markey.uky.edu or the UK Markey Cancer Center Facebook page for more information. Click the images below to hear student read excerpts from Cancer in Appalachia: A Collection of Youth Told Stories   For more information about : Appalachian Career Training in Oncology Program ACTION Books Connect with the UK Markey Center Online Markey Cancer Center On Facebook @UKMarkey On Twitter @UKMarkey

Season 10, Episode 1 of the PQI Podcast kicks off with a global perspective on cancer care, featuring Eoin Tabb, a leading oncology and haematology pharmacist in Ireland. Eoin serves as Chief 2 Pharmacist for Clinical Cancer Services at University Hospital Waterford, hosts the Irish Haematology Oncology Podcast, and is the Chairperson of the Irish Pharmacy Haematology Oncology Society. In this episode, he shares insights into: • How oncology and haematology pharmacy practice is structured in Ireland • The role of pharmacists within multidisciplinary cancer care teams • How digital health and artificial intelligence are being applied in real-world oncology settings • Opportunities for shared learning and collaboration across oncology systems

How This Is Building Me, hosted by world-renowned oncologist D. Ross Camidge, MD, PhD, is a podcast focused on the highs and lows, ups and downs of all those involved with cancer, cancer medicine, and cancer science across the full spectrum of life's experiences.In this episode, Dr Camidge sat down with Robert Kantor, MD. Dr Kantor is associate medical director of Medical Oncology & Hematology at Private Health Management.Drs Camidge and Kantor reflected on Dr Kantor's decades-long career. Inspired by his father's devotion to patients, Dr Kantor fast-tracked his education, entering medical school at Wayne State University without completing an undergraduate degree. Following fellowship, he intentionally chose private practice over academic oncology to focus on direct patient care and making a difference in the lives of patients' families.Dr Kantor's career illustrates the shifting landscape of American medicine. He has navigated various oncology practice models, including a corporate merger that he felt compromised patient care. In 2008, he took the risk of launching his own solo practice, successfully bringing trusted staff and a dedicated patient base with him.Dr Kantor eventually retired from clinical practice due to burnout, which was exacerbated by corporate management challenges and the inefficiencies of electronic medical records. His retirement evolved into an "encore career" as an associate medical director for Private Health Management. In this consultative role, he provides clinical oversight for complex oncology cases, helping patients navigate toward personalized cancer vaccines, clinical trials, and cutting-edge therapies. Dr Kantor expressed that this work has brought him renewed enthusiasm for the field of oncology, as it allows him to use his decades of experience with a basis of a better work-life balance. He remains passionate about how these high-end, personalized technologies will eventually make their way into routine clinical practice to benefit the broader patient population.

Have you longed to integrate your Christian faith into your patient care—on the mission field abroad, in your work in the US, and during your training? Are you not sure how to do this in a caring, ethical, sensitive, and relevant manner? This “working” session will explore the ethical basis for spiritual care and provide you with professional, timely, and proven practical methods to care for the whole person in the clinical setting. https://www.dropbox.com/scl/fi/qpah9kh1lttg6cm1jjop9/Bob-Mason-Ethics-of-Spiritual-Care-revised.pptx?rlkey=0emve2ja8282nv8xc4uinq1hg&st=9033htwx&dl=0

Sarah Gromko and Matthew Zachary go back to SUNY Binghamton in the early 1990s, when they were barely 19 and living inside rehearsal rooms. She starred in campus musical theater productions. He served as pianist and music director for many of those shows and played rehearsal piano for the THEA101 repertory company. This episode reunites two former theater nerds who grew up and took very different paths through art, illness, and work that still circles the same truth.Gromko trained as a singer and composer, studied film scoring at Berklee College of Music, worked in New York and New Orleans, then moved into healthcare as a speech language pathologist and recognized vocologist. She explains aphasia, apraxia, dysarthria, and dysphagia with clarity earned from the clinic. She recounts helping a 16 year old gunshot survivor in New Orleans speak again using Melodic Intonation Therapy. The conversation covers voice banking for ALS, gender affirming voice care, and the damage caused when medicine confuses speech loss with intelligence loss. The result feels like an epic reunion powered by 1990s nostalgia and sharpened by decades of lived consequence.RELATED LINKSSarah GromkoGramco VoiceMelodic Intonation TherapyFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode, Antonia and Andrew discuss the February 18, 2026 issue of JBJS, along with an added dose of entertainment and pop culture. Listen at the gym, on your commute, or whenever your case is on hold! Link: JBJS website: https://jbjs.org/issue.php Sponsor: This episode is brought to you by JBJS Clinical Classroom. Subspecialties: Knee, Oncology, Pediatrics, Shoulder, Hand & Wrist, Orthopaedic Essentials, Trauma, Spine Chapters (00:00:03) - Case is On Hold(00:00:45) - Episode 100(00:03:03) - Sneak Preview: Miller Review Course(00:03:42) - AI Generated Text in Orthopedics(00:05:36) - AI in Orthopedics: The Promised Land(00:13:44) - Artificial Intelligence in orthopedic and sports medicine(00:16:27) - Osteo and Sports Medicine Editorial Policies on AI(00:24:42) - How to Write a Paper With a Computer(00:25:16) - Deep Learning Model for Differentiating Neoplastic Fractures from Non(00:31:36) - The Ms. Cleo Phone Paradigm(00:32:34) - Machine Learning and Neoplastic Fractures(00:37:05) - AI-driven CT MRI Image Fusion and Automatic ACL Reconstruction(00:39:05) - A 100 Episodes of JBGS: Thank You!(00:40:46) - Aisha Abdeen Is The Next Co-Host!

Send a textAt this point in exam prep, many oncology physical therapists find themselves asking, “Is it too late?” And this LOADED question often comes with fear, pressure, and self-doubt.In this episode, we talk through how to think about this question honestly and calmly, how fear distorts decision-making, and why discernment is a critical professional skill.We cover:• Why this question shows up late in exam prep• The difference between panic-based and clarity-based decisions• Why pausing is not the same as quitting• How honest decisions protect long-term confidenceLooking for more structure and clarity?You can find a visual walkthrough of this decision point in the YouTube playlist here:https://youtube.com/playlist?list=PLZrwPMnzMtblj9rgmUIw7PJCQ8yGJ9IFX&si=-FMqrrcXf9QU2DQ7 Looking for more structure and clarity?If you're preparing for the ABPTS Oncology Specialty Exam and feeling overwhelmed or unsure what to focus on, I've created a short YouTube playlist designed to help you study with more clarity and confidence.These videos walk through prioritization, common pitfalls, and how to think about exam prep more strategically — without Follow TheOncoPT on Instagram.Follow TheOncoPT on LinkedIn.

Brad Kahl, MD, Siteman Cancer Center, St. Louis MO Recorded on January 27, 2026 Brad Kahl, MD Professor of Medicine Division of Oncology, Department of Medicine Washington University School of Medicine Director, Lymphoma Program Siteman Cancer Center St. Louis, MO In this episode, join Dr. Brad Kahl, Director of the Lymphoma Program at the Siteman Cancer Center in St. Louis, Missouri, as he delivers a concise and practical overview of chronic lymphocytic leukemia (CLL), from initial disease presentation to key diagnostic considerations. Dr. Kahl discusses the prognostic value of cytogenetic testing and its impact on treatment selection and reviews currently approved therapeutic options alongside notable updates from the latest American Society of Hematology (ASH) meeting. He also examines emerging agents and ongoing clinical trials that are shaping the future CLL treatment landscape. The conversation further explores strategies for managing side effects, addressing complications, and supporting patients and caregivers. Tune in for this timely and informative discussion! Additional Blood Cancer United Resources: Blood Cancer United Accredited and Non-Accredited Healthcare Professional Education Blood Cancer United Resources for Patients

This episode examines the role public policy plays in impacting lung cancer treatment and research. The world has made tremendous progress in the treatment of lung cancer over the past decade, and much of that progress is the result of supportive public health policies. As we look to the future, healthcare policy is sure to play an even bigger role in further improving patient outcomes, but many challenging barriers exist on a global scale. Host: Dr. Stephen Liu Guests: Professor Andreas Charalambous, Chair of the Department of Nursing and Professor of Oncology and Palliative Care at the Cyprus University of Technology. Professor Nicole Rankin, Head of the Evaluation and Implementation Science Unit at the Melbourne School of Population and Global Health of the University of Melbourne Dr. Samuel Kareff, thoracic medical oncologist at the Eugene M. and Christine E. Lynn Cancer Institute and Clinical Assistant Professor at Florida Atlantic University

Today's conversation is a deeply personal look at what it means to be diagnosed with breast cancer at just 30 years old. We often hear the statistics that more young women are being diagnosed, but numbers can't capture the shock of finding a lump before you think you're even old enough to worry… or the life-altering shift that happens when you are put into medically induced menopause. Caroline McNally knows the struggles of being in the thick of treatment and the isolation of being diagnosed younger than most. But she also knows about strength, hope and learning how to advocate for herself and others.

Is it time to trade your scrubs for a corporate career? In this episode, we sit down with Sydney Gramuglia, a Registered Nurse who successfully transitioned from bedside burnout to a high-impact, 6-figure role as an Oncology Clinical Educator at Eversana partnering with Sun Pharma. Sydney didn't have prior sales experience, and the job she landed wasn't even listed in her state—but she beat out veteran candidates anyway. Today, we're pulling back the curtain on the "Medical Sales U" blueprint she used to master a grueling 5-round interview process and land her dream job in the pharmaceutical industry.INSIDE THIS EPISODE:*The "Experience" Myth: Why "not enough experience" is usually a cover for "not enough preparation."*The LinkedIn Transformation: How Sydney went from 20 connections to 500+ and got headhunted by hiring managers.*The Mock Presentation: The exact 40-step rehearsal strategy Sydney used to master complex MOA (Mechanism of Action) and PD-L1 pathways.*Clinical Educator vs. Sales: Understanding the different paths for nurses in pharma.*The Contract Partnership: How the Eversana and Sun Pharma collaboration works.CHAPTERS:0:00 – Meet Sydney: From Bedside Nurse to Pharma Pro2:15 – The "Depressing" Reality of Nursing during COVID5:00 – Finding a Passion for Oncology7:30 – Why Your LinkedIn Profile Is Your New Resume9:15 – Breaking Down the Sun Pharma Offer13:45 – Clinical Educator vs. Sales: Which is right for you?16:10 – The Brutal Rejection that changed everything23:50 – Preparing for the 5-Round Interview Gauntlet25:30 – How to Ace a Mock Clinical Presentation31:00 – The Power of the Medical Sales U Community36:45 – Lifestyle Design: The perks of a corporate clinical role39:30 – Exploring Charleston: Best food & dog-friendly spotsCONNECT WITH Sydney Gramuglia - https://www.linkedin.com/in/sydney-gramuglia/READY TO BREAK INTO MEDICAL SALES? We help professionals transition into top-tier medical sales roles: medicalsalesu.com/#MedicalSales #NurseCareerChange #PharmaJobs #ClinicalNurseEducator #MedicalSalesU #NursingBurnout #CareerPivot #SunPharma #Eversana #MedicalDeviceSales #HealthcareInnovation

This episode features Selwyn M. Vickers, MD, FACS, a pancreatic cancer surgeon and president and CEO of Memorial Sloan Kettering Cancer Center in New York. During the American College of Surgeons Commission on Cancer Oncology Lecture at Clinical Congress 2025, Dr. Vickers discussed a transformative era in cancer care, where scientific breakthroughs are reshaping cancer therapeutics and redefining the role of surgeons. Talk about the podcast on social media using the hashtag #HouseofSurgery

On today's Good Day Health Show - ON DEMAND…Dr. Jack Stockwell, a NUCCA Chiropractor and GAPS Practitioner in SLC, UT (866.867.5070 | ForbiddenDoctor.com | JackStockwell.com), covers the the biggest news in the health and wellness space from a holistic, naturopath perspective. In this episode, Dr. Jack goes in depth on the topic of cancer. It's frightening, toxic, expensive, dangerous, and terminal in many cases. Oncology, cancer treatment, is the only branch of medicine where the doctors can sell their own cancer drugs to their cancer patients. Continuing on, Dr. Jack explains what you can do to minimize your chances at developing cancer, especially if you're predisposed, and what increases your likelihood of developing some form of cancer over your lifetime. Lastly, Doug joins Dr. Jack to discuss fried foods, especially those that use vegetable oil. More research coming to the surface that showcases frying food in vegetable oil can have nearly the same effect on your overall health as cigarettes. Website: GoodDayHealthShow.com Social Media: @GoodDayNetworks

Brachytherapy is an inside-out radiation approach to treating tumors that may offer advantages over external beam radiation in some situations. Samuel Marcrom, M.D., a radiation oncologist, discusses how brachytherapy differs from external beam radiation including its situational advantages and challenges, as well as common uses. He explains patient selection, treatment logistics, and the UAB patient experience.

In this week's episode, Blood editor Dr. Laurie Sehn interviews authors Drs. Anastasios Karadimitris and Maria Carolina Florian on their papers published in Volume 147 Issue 2 of Blood. Dr. Karadimitris' paper "Off-the-shelf dual CAR-iNKT cell immunotherapy eradicates medullary and leptomeningeal high-risk KMT2A-rearranged leukemia", discusses the success of bispecific CAR-iNKT cells targeting CD19 and CD133 in pre-clinical models, prompting the clinical development of this class of product. Dr. Florian's paper, "A Notch trans-activation to cis-inhibition switch underlies hematopoietic stem cell aging" proposes that the Jagged2/Notch interaction is a key regulator of hematopoietic stem cell divisional symmetry during aging and offers insights that may inform strategies to restore regenerative function in aged hematopoiesis. 

On this episode of the NC State Philanthropy Podcast, we're joined by Hyemi Sevening, assistant dean of philanthropy for the College of Veterinary Medicine (CVM), to learn how donors can partner in its life-changing work. CVM is an invaluable component of NC State's land-grant efforts, enabling the university to benefit animals — and people — across North Carolina and beyond. From training tomorrow's veterinarians and ensuring the state's food supply is safe to helping heal a beloved pet and much more, the college stands at the forefront of making the world a healthier and happier place through applied science. Medicine at CVM extends far beyond emergency care for cuts or broken bones, though. Oncology, cardiology, neurology and other specialized departments diagnose and treat all kinds of ailments in all kinds of animals. Much of the research taking place within the college's cutting-edge facilities also holds implications for human health. As the only veterinary college in North Carolina, CVM provides an extraordinary philanthropic opportunity. Donors can benefit CVM's students, faculty and staff through scholarships, professorships and programmatic support, as well as directly impact clients and patients of the college's veterinary hospital by helping cover the costs of medical care. Whatever your veterinary passions, there's a way to make your mark by giving to CVM. Visit cvm.ncsu.edu to learn more about the College of Veterinary Medicine, and click here to learn how you can support its work on Day of Giving 2026. If you'd like to hear even more stories of Wolfpack success, subscribe to the NC State Philanthropy Podcast today via Apple Podcasts, Spotify, Stitcher or Podbean. Please leave a comment and rating as well to let us know how we're doing. Transcript available here.

In this episode of Denatured, Jennifer C. Smith-Parker speaks with Dr. Rob Monroe, Vice President and Chief Scientific Officer of Oncology at Danaher Corporation and Chief Medical Officer at Leica Biosystems, and Jennifer Fakish, Vice President and Franchise Head of Oncology at Danaher Corporation. We'll be discussing how antibody drug conjugates (ADCs) are transforming cancer care and with AI-powered pathology, doctors can now measure her HER2 more precisely to match patients with the best treatments. HostJennifer Smith-Parker, Director of Insights, BioSpaceGuestsDr. Rob Monroe, Vice President and Chief Scientific Officer, Oncology, Danaher Corporation; Chief Medical Officer, Leica BiosystemsJennifer Faikish, Vice President and Franchise Head, Oncology, Danaher CorporationDisclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

Olufunmilayo “Funmi” Olopade, director for the Center for Clinical Cancer Genetics and Global Health at the University of Chicago, credits her Nigerian upbringing for her focus on global cancer genetics.“My Yoruba culture really worships our ancestors and the people before us,” Olopade said on the Cancer History Project podcast. “And so that's why I was able to really say, ‘Okay, let's lay the foundation for genetics. Let's go to Nigeria.'”Olopade appears on this special Black History Month episode of the Cancer History Project Podcast in conversation with Robert A. Winn, director and Lipman Chair in Oncology at VCU Massey Comprehensive Cancer Center and guest editor for The Cancer Letter for Black History Month highlighting some of the giants in the field of cancer research.This episode is sponsored by City of Hope, the American Society of Clinical Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, and the University of Texas MD Anderson Cancer Center.Olopade is certainly a giant in cancer genetics and global health.“For those of you who don't know, Dr. Olopade is not only the director of the Center for Clinical Cancer Genetics and Global Health at the University of Chicago, but she is really a giant in the field and internationally renowned in the context of her expertise in breast cancer,” Winn said on the podcast. “By the way, for those of you who thought you knew Dr. Olopade, remember that she is a really rare, not only National Academy, but in that top 1% of 1% of the 2025 MacArthur Fellowship, also known as the Genius Grant.”On this episode of the Cancer History Project Podcast, Olopade shares her story of immigrating to the U.S. from Nigeria to pursue medicine, and finding her way to becoming a leading expert in oncology.“For us to honor Black History Month, we have to honor all the people who mentored us, who were ahead of us,” Olopade said. “For me, my father was a pastor, and my parents really wanted a doctor. I had big brothers and sisters, I was number 5 of 6 children, and there was just one last chance to find a doctor in the family. Because in those days, growing up in Nigeria, you were either a teacher or a pastor, or and then in his generation he became a pastor.”Growing up in Nigeria, Olopade was deeply influenced by the health disparities she saw due to lack of healthcare access, which initially sparked an interest in cardiology.Explore related articles and read the full transcript: https://cancerhistoryproject.com/article/funmi-olopade-podcast/ 

Host: Brian P. McDonough, MD, FAAFP Guest: Christopher T. Chen, MD What if a simple blood draw could reveal whether a patient is responding to treatment before surgery? That question is at the heart of a study presented at the 2025 ESMO Congress, which investigated neoadjuvant immune checkpoint blockade in mismatch-repair-proficient (MMR-p) colon cancer. In addition to confirming that combination immunotherapy prior to surgery is a safe and feasible approach, the study also found that circulating tumor DNA (ctDNA) levels correlated with both tumor burden and early treatment response. Joining Dr. Brian McDonough to unpack these insights is Dr. Christopher Chen, Assistant Professor in the Division of Oncology in the Department of Medicine at Stanford University School of Medicine.

We heard stories of physicians practicing in the USA in a specialty different from the ones they originally trained in, perhaps even from a different country. In this episode, Dr. Czarnkowski shared with us about his journey of how he first got interested in medicine, then gynecological oncology, and finally to psychiatry as well as his insights and hopes for the field of psychiatry. Trigger Warning: suicideDr. Czarnkowski (Tscharnkoffsky), is an Affiliate Associate Professor of Psychiatry at Loyola University Chicago Stritch School of Medicine and an Attending Psychiatrist at the Edward Hines Jr. VA Hospital, where he also serves as Director of Emergency Psychiatry Services and provides care in the Acute Recovery Clinic and outpatient mental health. He previously held faculty and consultation-liaison roles at the University of Illinois at Chicago and served at Advocate Christ Medical Center, including leadership of CL and Acute Inpatient Psychiatry services.Dr. Czarnkowski earned his medical degree from Jagiellonian University Medical College in Krakow, completed postgraduate training in gynecological oncology in Poland and the UK, and completed psychiatry residency at the University of Illinois at Chicago. He is board certified in General Psychiatry and Consultation-Liaison Psychiatry. He's clinician-educator, he teaches key residency curricula, supervises trainees and medical students across emergency and outpatient settings, and has received multiple institutional awards for teaching excellence including Dept. of Psychiatry Chairman's Award for Dedication in Teaching and Resident's Education and was a three time recipient of Wolf and Kettle Award.Episode produced by: Deborah ChenEpisode recording date: 12/02/2025www.medicuspodcast.com | medicuspodcast@gmail.com | Donate: http://bit.ly/MedicusDonate

3人で前立腺癌、腎癌、尿路上皮癌の2025をレビューしました。

How do breakthroughs in the lab become real-world treatments that save lives? In this episode, Professor Stephen Maher of Trinity College Dublin joins us to discuss the rapidly evolving field of translational oncology and how cutting-edge research is shaping the future of cancer therapy. As a leading expert in radiation research and Director of Postgraduate Studies for the School of Medicine at Trinity, Stephen focuses on a critical question: why do some cancers respond to treatment while others resist it? His work examines the role of microRNAs, tumor hypoxia, and DNA damage response in shaping how cancers react to chemotherapy and radiotherapy — with particular attention to oesophageal and pancreatic cancers. In this episode, we explore: ·       Where anti-cancer therapeutics are headed in the coming years ·       How radiation research is evolving to improve treatment precision ·       Why translational oncology is essential for turning discovery into patient care ·       How treatment resistance forms — and what researchers are doing to overcome it After earning his Ph.D. in Oncology at RCSI and completing a fellowship at the National Cancer Institute in Maryland, Professor Maher has dedicated his career to bridging the gap between scientific discovery and clinical impact. He leads major national and international collaborations and has helped build advanced radiotherapy and hypoxia research programs at Trinity's Translational Medicine Institute. Learn more about Professor Maher and his work here. Episode also available on Apple Podcasts: https://apple.co/38oMlMr 

Send a textStudying for the ABPTS Oncology Exam while working full-time can make it feel like you're never doing enough. When time is limited, HOW you study matters more than how long you study.You'll hear why busy clinicians often default to passive studying, how time pressure increases second-guessing, and what actually helps when your schedule is full.In this episode, we cover:• Why time scarcity increases decision fatigue• The difference between familiarity and confidence• Why longer study sessions aren't always more effective• How structure reduces mental loadLooking for more structure and clarity?If visual guidance would be helpful, you can find related videos in this YouTube playlist:https://youtube.com/playlist?list=PLZrwPMnzMtblj9rgmUIw7PJCQ8yGJ9IFX&si=-FMqrrcXf9QU2DQ7 Looking for more structure and clarity?If you're preparing for the ABPTS Oncology Specialty Exam and feeling overwhelmed or unsure what to focus on, I've created a short YouTube playlist designed to help you study with more clarity and confidence.These videos walk through prioritization, common pitfalls, and how to think about exam prep more strategically — without Follow TheOncoPT on Instagram.Follow TheOncoPT on LinkedIn.

In honor of the International Day of Women and Girls in Science, we sit down with Megan Kamm, Head of Global Clinical Project Management at CTI, and Dr. Amanda King, nurse practitioner, PhD, and clinical researcher in oncology and rare disease. Together, they explore their career paths, early scientific inspirations, the promise of personalized medicine, and how women are driving innovation across clinical research. Their conversation offers practical advice, powerful personal stories, and a look at breakthroughs shaping the future of health care. 01:12 — Megan's Career Journey (Clinical Research → Global Leadership)From research coordinator to leading CTI's global clinical project managementfunction. 02:17 — Amanda's Path (Clinician-Scientist in Oncology& Rare Disease)A nurse practitioner and PhD with deep experience across pediatric critical care, oncology, and research. 03:07 — What Sparked Their Interest in ScienceEarly strengths in STEM, curiosity, and real-world exposure that shaped career direction. 04:53 — A Personal Story That Shaped a CareerAmanda shares how childhood experiences with cancer influenced her calling in healthcare and research. 05:49 — Turning Complex Science into Real-World TrialsMegan explains what it's like to help move early concepts into tangible clinical studies with a path to patients. 07:12 — Why Rare Disease Research Hits DifferentAmanda describes the urgency—and reward—of trials where no standard of care exists. 07:38 — Where Innovation Is Headed: Personalized MedicineTargeted therapies, mutation-driven treatment decisions, and what that means for outcomes. 08:15 — The Promise of Cell & Gene TherapyHow technology is enabling potential one-time treatments and even cures—for previously untreatable diseases. 09:12 — Challenges Women Still Face in STEMBeing underestimated, navigating bias early in a career, and the role mentorship plays in resilience. 11:06 — Advice for Girls & Young Women Exploring STEMDefine success on your own terms, find the right environment, and learn what you truly value. 12:30 — Habits That Help: Mentorship + CuriosityShadow, ask questions, stay open to pivots, and keep learning as roles evolve. 14:12 — A Practical Takeaway: Don't “Single-Track” Your SkillsetMegan on blending science with business skills to expand options and impact. 16:01 — Start Early: Intern, Shadow, ExploreAmanda's recommendation to get real exposure early because STEM has more paths than most people realize.

Those who hope to honor God and advance Jesus' Kingdom face powerful opposition from spiritual, physical, and psychological enemies. Successful launching and long term fruitfulness depends on recognizing and, in dependence on the Holy Spirit, waging war against those enemies.

Today, our guest is a transformative figure in bowel cancer treatment. Professor Jenny Seligmann, a Consultant Medical Oncologist and Professor of Gastrointestinal and Translational Oncology at the University of Leeds, is renowned for leading the groundbreaking FOxTROT and ARIEL trials. These studies challenged traditional practices by demonstrating the advantages of administering chemotherapy before surgery, a change now saving lives and influencing worldwide protocols. As a devoted mentor and a prominent participant in Cancer Research UK's initiatives, she joins us to explore how we can personalise cancer treatment more effectively and discuss the future prospects for gastrointestinal cancer therapies. Welcome, Professor Seligmann.For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.

Matt Hampton and Dr Tom Ingegno came into my world the way the best guests always do. They found me first. They pulled me onto their Irreverent Health Podcast, a show that blends medicine, curiosity, and unapologetic nonsense the same way Gen X kids blended Saturday morning cartoons with nuclear-war anxiety. We recorded together, we went off the rails together, and by the end I told them the rule. If you ever come to New York, you sit in my studio. No exceptions.They showed up. They took the hot seat. They told Alexa to shut up. They joked about Postmates. They compared bifocals before I even hit record. From there it turned into a full blown eighties time machine powered by weed policy, AI diagnostics, acupuncture philosophy, art school trauma, cannabis data science, paranormal detours, and the kind of deep cut pop culture references only Gen X survivors can decode.Matt builds AI systems. Tom heals people with needles and a lifetime of East Asian medicine. Together they make healthcare funny without pretending it works. They remind you that curiosity carries weight when the system collapses under its own stupidity.This episode is a reunion of three loudmouths raised on Atari, late night cable, and the hard lesson that you either tell the truth or get flattened by it. Go subscribe to Irreverent Health. These guys earned it.RELATED LINKS• Irreverent Health Podcast• Matt Hampton – Consilium Institute• Envoy Design• Dr. Tom Ingegno – Charm City Integrative Health• The Cupping Book• You Got Sick—Now What?• Matt Hampton on LinkedIn• Dr. Tom Ingegno on LinkedInFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode of the Heart podcast, Digital Media Editor, Professor James Rudd, is joined by Professor Kazuaki Negishi from Sydney, Australia. They discuss the optimal use of imaging to detect cardiac effects of cancer therapies. If you enjoy the show, please leave us a positive review wherever you get your podcasts. It helps us to reach more people - thanks! Link to published paper: https://heart.bmj.com/content/111/22/1057

Listen now to the latest episode of JCO Cancer Stories: The Art of Oncology, North Star, by Dr Manuela Spadea. As a pediatric oncologist, Spadea shares a luminous, gut-honest reflection that reminds us that beyond protocols and outcomes, the deepest medicine is presence. TRANSCRIPT Narrator: North Star, by Manuela Spadea, MD  Mikkael Sekeres: Welcome back to JCO's Cancer Stories: The Art of Oncology. This ASCO podcast features intimate narratives and perspectives from authors exploring their experiences in oncology. I am your host, Mikkael Sekeres. I am professor of medicine and Chief of the Division of Hematology at the Sylvester Comprehensive Cancer Center, University of Miami. What a pleasure it is to have joining us today Manuela Spadea, an assistant professor of pediatrics at the University of Turin in Italy and consultant oncologist at the Regina Margherita Children's Hospital in Turin, Italy. We will discuss her Journal of Clinical Oncology article and second place winner in our Narrative Medicine Contest, "North Star." At the time of this recording, our guest has no disclosures. We have agreed to address each other by first names. Manuela, thank you for contributing to the Journal of Clinical Oncology and to our Narrative Medicine Contest, and especially for joining us to discuss your winning article today. Manuela Spadea: Hi Mikkael. Thank you for having me today. It is a pleasure and an honor being invited to speak with you. Mikkael Sekeres: No, the pleasure and honor is mine, I promise. You know, on these podcasts, I often like to ask our guests to tell us something about yourself. Where are you from, and walk us through your career and where you are right now. Manuela Spadea: Sure. I am from Italy. I work in Turin, where I work as a consultant pediatrician, a consultant oncologist, and also as an assistant professor of pediatrics. So my work is divided in these two duties: clinical duties on one hand and on the other hand, research and also teaching activities. I was drawn to choose pediatric oncology because this sits at the intersection of science and humanity, in my opinion, of course. I think that in pediatric oncology, we face different and several challenges, so we need to perform at our best in diagnosis, treatment, and whatever. But also, we are asked to not forget being human and to connect always with our children and their families. So it was basically this intersection, this connection between science, research on one hand, and humanity and heart on the other hand that led me to what I am today. Mikkael Sekeres: It is a fantastic explanation, and it is interesting how you have framed that, that there is an aspect of arts and humanities that you have found in focusing on pediatric hematology oncology. I do think that is more so than what we face in adult oncology. Manuela Spadea: I think that it is kind of different because if you think about our world and you think about a sentence, just putting the words 'child', 'cancer', and 'death' in the same sentence is very hard to think about. An adult is someone that has already had the chance and the gift to grow up. Mikkael Sekeres: Huh. It is an interesting perspective on it. Manuela Spadea: Yeah. A child is someone who is growing up and cancer stays in between his possibility to become an adult or not. Mikkael Sekeres: So the emotional burden right out of the gate of having a child with cancer and the possibility of death and the reaction to the compromise of a full life and the shortening of a full life automatically invokes that extra step of humanity and arts and how we have to approach a medical situation. I had not heard somebody put that into a concise phrase like that before, but you are absolutely right. When did you start writing narrative pieces? Manuela Spadea: I started writing when I was an adolescent, basically. And writing for me was a way to cope with whatever kind of feeling I felt during my life and during what I experienced as a human beforehand. But thereafter, when I became a clinician, writing was a way to cope with difficult shifts or hard nights in which you are asked to make very hard decisions as a clinician. Mikkael Sekeres: Often, either on this podcast or outside of it, doctors will approach me and want to get into writing and write a piece. And I think what many people do not realize is it is entirely possible later in life to start writing and to be very skilled at it. Many of our authors for JCO's Art of Oncology, though, have been writing their entire lives. It is not like they woke up one morning and decided, "Today I am going to write and I am going to write creatively." We have all been working on it for decades. Manuela Spadea: Sure. Mikkael Sekeres: I wonder who are some of your favorite authors or are there writers who have influenced your own writing? Manuela Spadea: I would go with Paulo Coelho and Alda Merini. The reasons are very different because from Paulo Coelho, I learned how to express life as a journey and how to use and exploit, of course, symbolic images to express what we want to tell to our readers. From Alda Merini, I learned that pain and suffering are worthy of being mentioned and they still deserve a place in our writings. And she taught me how to collocate, how to find the right place and the right words to express pain and suffering that are parts of our life, of course, in pediatric oncology, of course, and are worthy being expressed in a manner that can reach our readers and touch them. Mikkael Sekeres: Well, as you have beautifully in your essay, I wonder if you could give us an example of a symbolic image. Manuela Spadea: For example, referring to my essay, "North Star." I chose the North Star because it is a very important image because it recalls to us about being a fixed point in a collapsing world. Basically, it is the world of our children that is collapsing and you are the one who represents this fixed point, this anchor. Mikkael Sekeres: So in your essay, which our entire editorial staff just loved, you write about, and I am going to quote you to you, which is always a little bit awkward, but here I go. You write about "the unbearable beautiful vulnerability of being a North Star for a child with cancer." And you write, "We never call it that, of course, not in rounds, not in protocols, but that is what we become: a fixed point in a collapsing sky. When nothing else makes sense, when numbers fail and outcomes blur, they look to us, not because we promise survival, but because we promise we won't leave." Wow. I mean, that is an incredible collection of sentences. I wonder, in our relationships with our patients, when does that happen? When do we become a North Star? Manuela Spadea: I think that we become a North Star when our patients experience our humanity because they can trust us, not only for our degrees or our experience as clinicians, physicians, researcher, whatsoever. They trust us as a North Star when they feel that we are empathetic with them, when they know that we are feeling what they are experiencing. And so they leave their feelings to us, they share their feelings and they begin to connect with us. Mikkael Sekeres: When does that happen in the timeline of when we meet a patient? Is that something that can happen at our very first meeting where a patient may identify us or a member of our team as their North Star, or is that something that only happens over time as we build trust and build empathy? Manuela Spadea: It is definitely something that happens over time, day by day. Sometimes, but only occasionally, in my opinion, it can happen on the very first days, for example, the days in which we give them the diagnosis. But these are only small occasions because in the majority of cases, in my experience, the trust is built day by day. Mikkael Sekeres: There are also times that doesn't happen, though, right? What are those scenarios like when either patients do not need us to be a North Star or when that deep connection never happens? Manuela Spadea: I think that these are very challenging situations. It can happen when outcomes blur, of course, because sometimes patients are experiencing too much suffering and they cannot share with us because they are not able of sharing with us their feelings. Sometimes it is just because you are not their North Star. Sometimes it is inexplicable, basically. "I do not trust you, not because you are not what I am looking for, but because I do not feel I can trust you. And I do not know how to explain because I cannot trust you." Mikkael Sekeres: It is interesting. It is complicated to develop that relationship where you become a North Star. It sounds like what you are saying is it is a combination of trust, first and foremost, honesty, attentiveness to a patient's needs, and time. Manuela Spadea:Sure. Mikkael Sekeres: In your piece, you write about a couple of patients you have treated, Eva and Cecilia, and you write, "In both Eva's and Cecilia's journeys, I was not the most experienced doctor in the hospital. I wasn't the one who had written the protocol they were enrolled in or published the paper that dramatically shifted their chances. But I was the one who stayed, the one they chose. Incredibly, this is both a gift and a responsibility." There is a lot in those sentences, Manuela. You give patients the agency to identify us as a North Star, not us. Can you talk about that a little bit? Manuela Spadea: I think that there is a word in pediatric oncology that could be used as recurrent. And this word is 'impossible'. Why I chose this word? Because we live impossible diagnosis. Let's be honest. Impossible diagnosis, impossible suffering, impossible losses. When you face the impossible, being a North Star without being burned out by this, it is accepting that you are going to face uncertainty just being present. Because you are not the one that will change the outcome, or you can't be sure that that child will have the chance to survive. So if you give the possibility to face the uncertainty, being sure that whenever it goes, you can just be present for your patient and remember every day to your patient that you are there for them. So basically you win. And on the other hand, you also need to protect yourself because being a North Star is a responsibility, as I wrote. And a responsibility can be overwhelming for the one who is responsible for that child. So in that case, the only thing that can protect you is taking the part of being a North Star with boundaries. So you should also try to maintain your objectivity as a clinician and protect that objectivity that allows you to also serve as a good clinician. Mikkael Sekeres: So I wonder if I could follow up on that a little bit. It is a lot of work to be a North Star, isn't it? I mean, we have to choose our words and our actions so very carefully when we are in a room with a patient and that patient's family. Do you think serving as a North Star contributes to burnout or is it actually the opposite? It keeps our work vibrant and real? Manuela Spadea: Good question. I think that it is both, indeed. I think that burning out comes not by being a North Star, but by being a North Star in isolation, without caring about yourself, without finding a way to cope with your grief, with your sense of fear because we are human, so it is basically we experience these feelings. I mean, if we do not have a way to cope and to protect our feelings, we can absolutely go into burnout. On the other hand, it can be very important thing for our work because it can give our work the possibility to be vibrant and real because we are allowed to take the journey of our patient in a moment in which their journey is very unbearable. This is also not only a responsibility, but also a very important place that we have in their lives. This is very beautiful for me. This is astonishing because we are allowed to enter our patients' lives in a very difficult moment, and we can walk with them. Basically, being present and walking through what cancer journeys reserve for them. Mikkael Sekeres: Well, I think that is a lovely place to end our podcast. What a real pleasure it has been to have Manuela Spadea, who is an assistant professor of pediatrics at the University of Turin, Italy, and consultant oncologist at the Regina Margherita Children's Hospital in Turin, Italy, to discuss her essay, "North Star." Manuela, thank you so much for submitting your article both to JCO and to our contest, and for joining us today. Manuela Spadea: Thank you, Mikkael. It has been an honor to share these stories with you. Mikkael Sekeres: If you have enjoyed this episode, consider sharing it with a friend or colleague or leave us a review. Your feedback and support helps us continue to have these important conversations. If you are looking for more episodes and context, follow our show on Apple, Spotify, or wherever you listen, and explore more from ASCO at asco.org/podcasts. Until next time, this has been Mikkael Sekeres for JCO Cancer Stories: The Art of Oncology. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Show Notes:Like, share and subscribe so you never miss an episode and leave a rating or review. Guest Bio: Dr Manuela Spadea is an Assistant Professor of Pediatrics at the University of Turin, Italy, and Consultant Oncologist at the Regina Margherita Children's Hospital, in Turin, Italy.

In this episode of Rounding@IOWA, Dr. Gerry Clancy sits down with breast cancer experts Dr. Katherine Huber‑Keener and Dr. Nicole Fleege for a discussion of modifiable and non‑modifiable risk factors, modern screening tools, and practical strategies clinicians can use to guide prevention and early detection. CME Credit Available:  https://uiowa.cloud-cme.com/course/courseoverview?P=0&EID=82146  Host: Gerard Clancy, MD Senior Associate Dean for External Affairs Professor of Psychiatry and Emergency Medicine University of Iowa Carver College of Medicine Guests: Nicole Fleege, MD Clinical Assistant Professor of Internal Medicine-Hematology, Oncology, and Blood and Marrow Transplantation University of Iowa Carver College of Medicine Kathryn Huber-Keener, MD PhD Clinical Associate Professor of Obstetrics and Gynecology - General Obstetrics and Gynecology University of Iowa Carver College of Medicine Financial Disclosures:  Dr. Gerard Clancy, his guests, and Rounding@IOWA planning committee members have disclosed no relevant financial relationships. Nurse: The University of Iowa Roy J. and Lucille A. Carver College of Medicine designates this activity for a maximum of 0.75 ANCC contact hour. Pharmacist and Pharmacy Tech: The University of Iowa Roy J. and Lucille A. Carver College of Medicine designates this knowledge-based activity for a maximum of 0.75 ACPE contact hours. Credit will be uploaded to the NABP CPE Monitor within 60 days after the activity completion. Pharmacists must provide their NABP ID and DOB (MMDD) to receive credit. JA0000310-0000-26-035-H99 Physician: The University of Iowa Roy J. and Lucille A. Carver College of Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Other Health Care Providers: A certificate of completion will be available after successful completion of the course. (It is the responsibility of licensees to determine if this continuing education activity meets the requirements of their professional licensure board.)      

Treatment is a significant part of overcoming breast cancer, but what about the mental, physical and emotional challenges this disease presents? Sarah Cipolla and Tawana Davis both relied on their faith to get through breast cancer. Through it all – the ups and downs and good times and setbacks – they had hope for better days and trusted in their faith. Hope and faith are powerful forces during challenging times. Susan G. Komen leads Worship in Pink, a nationwide program that brings breast health education to faith communities. Through this effort, Komen can reach people who don't participate in breast health care and people who rely on their faith to overcome life's challenges. Thanks to Merck and Novartis for supporting the Worship in Pink Program

In this episode of the Eye Believe Podcast, we're joined by Molly Vocino, LCSW, an oncology social worker at the Sidney Kimmel Comprehensive Cancer Center at Jefferson Health in Philadelphia.   Molly is passionate about ensuring all people have access to quality healthcare and compassionate support—especially individuals and families navigating serious illness.   In this conversation, she helps patients better understand the types of professionals available to support them throughout their cancer journey and how oncology social workers can play a critical role in care.   Together, we explore: What oncology social workers do and how they support patients and families How to find and access resources, including financial assistance and practical support Why emotional, social, and logistical care are just as important as medical treatment   This episode is a valuable guide for anyone facing cancer who may not know where to turn for help—or what support is available beyond the exam room.

Cardio-Oncology: Keeping the Heart Healthy During Cancer Treatment February 8, 2026 Yale Cancer Center visit: https://www.yalecancercenter.org email: canceranswers@yale.edu call: 203-785-4095

"You also want to deal with patient preferences. We do want to get their disease under control. We want to make them live a long, good quality of life. But do they want to come to the clinic once a week? Is it a far distance? Is geography a problem? Do they prefer not taking oral chemotherapies at home? We have to think about what the patient's preferences are to some degree and kind of incorporate that in our decision-making plan for treatments for relapsed and refractory myeloma," Ann McNeill, RN, MSN, APN, nurse practitioner at the John Theurer Cancer Center at Jersey Shore University Medical Center in Neptune, NJ, told Lenise Taylor, MN, RN, AOCNS®, TCTCN™, oncology clinical specialist at ONS, during a conversation about multiple myeloma treatment considerations. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by February 6, 2027. Ann McNeill has disclosed a speakers bureau relationship with Pfizer. This financial relationship has been mitigated. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to the treatment of multiple myeloma. Episode Notes  Complete this evaluation for free NCPD. ONS Podcast™ episodes: Episode 398: An Overview of Multiple Myeloma for Oncology Nurses Episode 395: Pharmacology 101: Monoclonal Antibodies Episode 372: Pharmacology 101: Proteasome Inhibitors ONS Voice articles: Effective Care Transitions Are Essential for New Multiple Myeloma Treatments New Multiple Myeloma Treatments Present New Challenges in Side Effect Management Reduce Racial Barriers and Care Inequities for Black and African American Patients With Multiple Myeloma ONS Voice FDA approval alerts ONS Voice oncology drug reference sheets: Belantamab mafodotin-blmf Daratumumab Motixafortide Selinexor Clinical Journal of Oncology Nursing articles: Journey of a Patient With Multiple Myeloma Undergoing Autologous Stem Cell Transplantation Optimizing Transitions of Care in Multiple Myeloma Immunotherapy: Nurse Roles Oncology Nursing Forum article: Facilitators of Multiple Myeloma Treatment: A Qualitative Study ONS books: Hematopoietic Stem Cell Transplantation: A Manual for Nursing Practice (third edition) Multiple Myeloma: A Textbook for Nurses (third edition) ONS course: ONS Hematopoietic Stem Cell Transplantation™ ONS Huddle Cards: Financial Toxicity Hematopoietic Stem Cell Transplantation (HSCT) Monoclonal Antibodies ONS Hematology, Cellular Therapy, and Stem Cell Transplantation Learning Library American Society of Clinical Oncology (ASCO)–Ontario Health: Treatment of Multiple Myeloma Living Guideline International Myeloma Foundation: Clinical Trials Fact Sheets Clinical Trial Support Resource Library Multiple Myeloma Research Foundation resource: Treatments for Multiple Myeloma To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "Typically for our first-line therapies, we use certain classes of drugs and some of them are proteasome inhibitors like bortezomib and carfilzomib. We also have IMiDs or immunomodulatory agents like thalidomide, lenalidomide, and pomalidomide. We have monoclonal antibodies, anti-CD38 monoclonal antibodies. Of course, we can never talk about treatment for myeloma without mentioning dexamethasone. It is an integral part of our treatment regimen. Most of our frontline therapies now are not just a single agent. They're not even doublets anymore. Typically, they're triplet therapies. And now in 2026, it's leaning more toward quadruplet therapies. By that, I mean you're taking a proteasome inhibitor, an immunomodulatory drug, dexamethasone, and an anti-CD38 monoclonal antibody all together to present patients with a good chance their induction therapy will lead to a good chance of them responding to treatment." TS 4:25 "[With] myeloma labs, there should be some indication after each cycle of therapy that the treatment is working. So, you don't have to do a whole myeloma panel, but maybe getting a monoclonal protein spike, maybe getting a free light chain assay, or maybe an immunoglobulin G or immunoglobulin A level, just to see if the treatment is working. So, those labs are crucial to determine whether the therapies are working. And again, the lab improvements usually correlate with the clinical presentation of the patient." TS 11:01 "There are active clinical trials ongoing with drugs like cell mods. Cell mods are the new oral anticancer agents for myeloma that have shown great promise with efficacy and safety profiles. And then there are other combinations that are showing a lot of promise. So, drugs that are already approved by the U.S. Food and Drug Administration (FDA). And I'm talking about pairing anti-CD38 monoclonal antibodies with bispecific T-cell engagers. If you do that, there has been some evidence that these combinations are very efficacious and responses are durable. And there are ongoing clinical trials and studies being done right now to see if these can be FDA-approved to pinpoint where they are as far as in comparison to other treatments." TS 20:10 "I always tell patients to try to participate in safe, and I want to stress safe, physical activity. So, I tell patients, the more you sit on the couch or you sit in the chair for most of the day, that unfortunately will make your pain worse. So, trying to get up and about and doing some physical activity, such as getting a physical therapy evaluation and a treatment program, no matter how passive or mild or gentle it is, can really help these patients with bone pain." TS 26:10 "I think it's important to realize that myeloma has had amazing advances in science, research and treatments. I think that all of these things coming together, all the science and clinical trials and everything like that, has led to a significant increase in overall survival of our patients, which ultimately is a great thing. We want patients to live longer and they're living longer with a very good quality of life. So, I think it's important to realize that myeloma is very well studied, very well researched, and it's still ongoing with many, many clinical trials." TS 36:04

As the number of patients and survivors of cancer grows each year, awareness of the disease's emotional toll—including depression, anxiety, and deep existential distress—is increasingly recognized as a critical aspect of cancer care. In response, psychedelic-assisted therapy is gaining attention as a promising alternative to traditional mental health interventions, providing relief for some patients. To shed light on the patient experience with this treatment, CANCER BUZZ spoke with breast cancer survivor Judy Wight; Jennifer Bires, MSW, LCSW, OSW-C, FACCC, executive director of Life with Cancer and Patient Experience at Inova Health System; and Manish Agrawal, MD, cofounder and CEO of Sunstone Therapies, about the human side of psychedelic-assisted therapy, promising existing research, and how it can shape the future of psychosocial care. "It's not that I'm a different person. It's more like I'm becoming the person I was meant to be. And all those layers of trauma and sadness...I've been able to shed a lot of that." – Judy Wight "When I started to learn about psychedelic-assisted therapy, read some of the patient accounts, and see some of the research, I said, 'I've got to learn about this. I think that this could be another tool that would be useful for people in this space where we don't have the perfect answer, and we don't have the perfect treatments.'" – Jennifer Bires, MSW, LCSW, OSW-C, FACCC "When I give talks around this, I have an iceberg. Above the iceberg I have chemotherapy, surgery, and radiation, and underneath the iceberg I have what's called psychosocial, psycho-spiritual, psychological care. And I think true cancer care is treating everything in the iceberg, not just what's above the water." – Manish Agrawal, MD   Guests: Jennifer Bires, MSW, LCSW, OSW-C, FACCC  Executive Director, Life with Cancer and Patient Experience Inova Health System Fairfax, VA   Judy Wight Breast Cancer Survivor   Manish Agrawal, MD Cofounder and CEO Sunstone Therapies REKINDLE Investigator   This podcast is sponsored by Reunion Neuroscience.   Resources: The REKINDLE Study ClinicalTrials (NCT07002034) REKINDLE Brochure Reunion Neuroscience Adjustment Disorder Associated With Medical Illness: Unmet Needs and Rationale for RE104 as a Novel Psychedelic Therapy Exploring Psychedelic-Assisted Therapy in Oncology Addressing the Psychological Burdens of Cancer on World Mental Health Day Psychosocial Care in Oncology: Advocating for Policy Changes that Improve the Culture of Care Collaborative Care: A Model for Embedding Counseling in Oncology and Palliative Care Spirituality and Cultural Humility: Core Components of Comprehensive Palliative Care Psychosocial Care in Oncology Collaborative Care: A Solution for Increasing Access to Psychosocial Care in Cancer Programs and Practices Scan to learn more about the REKINDLE study:  

Dr. Monty Pal and Dr. Atul Batra discuss the PLANeT study from India, which evaluated low-dose pembrolizumab in addition to neoadjuvant chemotherapy for triple-negative breast cancer, and its place among a growing body of international research on improving efficacy while reducing costs and toxicity with lower doses of immunotherapy. TRANSCRIPT Dr. Monty Pal: Hello and welcome to the ASCO Daily News Podcast. I'm your host, Dr. Monty Pal. I'm a medical oncologist, professor, and vice chair of academic affairs at the City of Hope Comprehensive Cancer Center, Los Angeles. My guest today, I think, is going to be a really riveting one. It's Dr. Atul Batra, who is an additional professor of medical oncology at the All India Institute of Medical Sciences, or AIIMS, in New Delhi. And he's also the senior author of the PLANeT study. It's a very compelling study that evaluated low-dose pembrolizumab in addition to neoadjuvant chemotherapy for triple-negative breast cancer. And it's really a big part of a growing body of research that's showing balanced efficacy when we use lower doses of immunotherapy instead of standard doses to reduce cost, as well as potentially toxicity. I think this has huge implications for our global audience, and I'm so thrilled to have you on the podcast today, Dr. Atul Batra, welcome. Dr. Atul Batra: Thank you, Dr. Pal. Dr. Monty Pal: And we'll just take it with first names from here since we're both friends. I have to give the audience some context. Atul, I had the great honor of visiting AIIMS New Delhi. For those that don't know, this is really, you know, the Harvard Medical School of India. It's the most competitive institution for medical training. And on the back end of that, there's also incredible resources when it comes to clinical trials and infrastructure. I just wanted to have you give the audience sort of a scope of the types of trials that you've been able to do at AIIMS New Delhi. Dr. Atul Batra: Thank you, Monty. So, I work at the All India Institute of Medical Sciences, and we had the honor and pleasure of having Monty here this month. And people are still in awe of his lectures that he delivered there. Coming back to our institute, so it's kind of a medical college. It's one of the oldest ones, it was built in 1956. We are lucky enough that we get the best of the residents and fellows because they have to go through an exam, a competitive exam, and mostly it's them who come to us and we're able to do some good work out here. Regarding the trials that we have conducted, we do conduct some investigator-initiated studies, and we try to answer the questions where we can help our own patients. Like, for example, this PLANeT study. Every other patient in the clinic was almost not able to afford Keytruda at the full dose, pembrolizumab, and we had a lot of evidence creeping in that a lower dose might be helpful. And that's how we planned this study. Before that, there are certain cancers that are peculiar to India, like gallbladder cancer, head and neck cancers. These are much more common in India as compared to the U.S., and there are some good studies that have been conducted from our own institute by our senior colleagues which have been presented at ASCO and published in the JCO. We also did the capecitabine hand-foot syndrome study that was known as the D-ToRCH study: 1% diclofenac gel that became the standard of care to prevent hand-foot syndrome.  So, that's kind of a brief overview of investigator-initiated studies. India is slowly and steadily becoming a partner of the global registration trials. And it's more recently, the last five years or so, we have seen that the number of phase 2 and phase 3 trials are increasing and we are able to offer now these trials as well to our patients. Dr. Monty Pal: That was a terrific overview. I just want to highlight for the audience, as we go through some of your discussions today around specific trials, the speed at which this can be done. Just for context, for me to accrue a clinical trial of 30 patients – I think many people have probably come across some of the work that I've done in the microbiome space – at a single institution, 30 patients, right, takes me about a year and a half, two years. We're going to go through some trials today where Dr. Batra and his team have actually, in fact, accrued close to 200 patients over a span of just a year, which is just remarkable by, I would say, any American standard. So, I see a real need for partnership and Atul, I'll kind of get back to that at the end. But without further ado, the focus of this podcast today, I think, is really this terrific presentation you gave in an oral session at ESMO and subsequently published in Annals of Oncology related to the PLANeT study. Would you give the listeners some context around what the study entailed and population and so forth? Dr. Atul Batra: So, we know the KEYNOTE-522 became the standard of care for triple-negative breast cancer, where Keytruda, when added at 200 mg, the standard dose every three weeks with neoadjuvant, increases the pCR from around 51% to 64% by a magnitude of around 13%. However, in India and other low-middle income countries, less than 5% of the patients actually have access to this dose of pembrolizumab. So, our standard of care was actually just chemotherapy till now. And this kind of led us to design this trial. There are data that come from previous trials conducted in India, from the Tata Memorial, done in head and neck space, some other studies done in Hodgkin's lymphoma, that a much lower dose, probably around one-tenth of the dose, works well in these cancers. So, that's where we designed the PLANeT study, where we gave the standard neoadjuvant chemotherapy in the control arm, and in the experimental arm we added 50 mg of pembrolizumab. This was given every six weeks for three doses. So, that's a total of 150 mg over the neoadjuvant period as compared to 1,600 mg that was given in the KEYNOTE-522 study. So, this was almost one-tenth of the study. Dr. Monty Pal: So, a tenth of the dose, which is just remarkable. I mean, that's just such an interesting concept. Dr. Atul Batra: And the results, when we – the primary outcome, this was a phase 2 study. We just wanted to see, is there a signal of activity? And to even our surprise, when we looked at the pathological complete response rates, in the control arm this was 40.5%, and in the experimental arm this was 53.8%. So, a difference came to around 13.3%; it was numerically, I mean, so much similar to what KEYNOTE-522 had with just these many doses. So, this was around 160 patients randomized over one year. We could randomize them in one year because of the load that we see. And the primary endpoint was met, and we could see that the path complete response did show a remarkable increase. We are still following these patients to see whether there is a difference in event-free survival at a longer follow-up. Until now, it's a small follow-up, so the number of events absolute, are different: four events in the experimental arm and 11 events in the control arm. So, we are seeing some signal even in this much short follow-up period as well. But we need to see more of what happens in the longer term. Dr. Monty Pal: That's so impressive. I wonder, with this lower dose, do you attenuate toxicity at all as far as you can gather? Dr. Atul Batra: So, although we shouldn't be doing kind of cross-trial comparisons, but if you look at thyroid dysfunction, we saw that around 10% of our patients had this thyroid dysfunction. This was compared to 15% in the KEYNOTE-522, that was a larger sample size though. But we're seeing that all the toxicities are somewhat less as compared to those in the standard dose. So, the exposure is less, but I mean, I can't really commit definitely on this. For this we would need much more data to say this with more confidence. Dr. Monty Pal: Yeah. I'm going to ask you a really tough question to follow up, and this is probably something that's on everyone's mind after reading a study like this. Is this something that is disease-specific that needs to be replicated across other histologies? The reason I ask this is, you know, you think about paradigms like, for instance, in the States we're toying between intravenous versus subcutaneous delivery of checkpoint inhibitors, and we have studies focused in specific histologies that might justify use across all histologies. With this particular phenomenon, do you think we need to do dedicated studies in renal cell or in colon cancer and other places where, you know, in selected settings we might use checkpoint inhibitors and then decide whether or not there's this dose equivalence, if you will? Dr. Atul Batra: That's a real tough one, though. But I'm happy to share that there are several ongoing studies within India currently. At our institute, my colleagues are leading studies in lung cancer space, cervical cancer. There was already a publication from Tata Memorial Hospital in head and neck cancers and we see that the signal has been consistent throughout. Regarding renal cancer, there was one study that was presented for sure at ASCO from CMC Vellore, that's again a center in South India. That was in RCC at a much lower dose. And for patients who cannot take the full dose, we actually are offering lower dose nivolumab in such patients and we are seeing responses. I mean, we haven't done those randomized trials again because the numbers are much lower in kidney cancers, we know. We could do this trial in triple-negative ones because we had support and we had numbers to conduct this trial. But I'm sure this should be a class effect. I mean, when we can get tumor-agnostic approvals, then some real-world data has come up in almost all tumors, we have seen that consistent effect across tumors. And as we speak of today, I'm also delighted to share that in India, yesterday, we had the first biosimilar of nivolumab and that's now available at a much, much lower price than the original patent product. There was a long ongoing lawsuit that was there, that's over now, and from yesterday onwards, I'm so happy to share here that we would have the first biosimilar of nivolumab that's available. That's going to bring the cost to almost like one-tenth already. Dr. Monty Pal: Wow. That's huge.  I'm going to be very selfish here for a second and focus on a study that is in the renal cell space that your group has done. You know, when it came out, I was really sort of intrigued by this study as well and it reflects sort of a different capability, I think, of AIIMS New Delhi, and that's in the, what I'm going to call, biomarker space. This, for the audience, was a prospective effort to characterize germline variants in patients with advanced kidney cancer. And it's something that we talk about a lot in the kidney cancer literature, whether or not we're missing a lot of these so-called hereditary patterns of RCC. Can you tell us a little bit about that study too? Dr. Atul Batra: Yeah, so that was led by one of our fellows, Chitrakshi Nagpal, and she's just completed her fellowship. And two years back we published that. So, that was done in almost 160 consecutive patients that we recruited over the span of just one year and we saw, apart from the common known mutations in RCC, that was around 5% or so, but a lot of other mutations were also seen that we don't generally see in kidney cancers and we see in other cancers like BRCA1, BRCA2 and others. We are still, I mean, doing those analyses to see whether we get more things out of there in the somatic: is there a loss of heterozygosity or was it just present and in there? Dr. Monty Pal: I thought it was a terrific study and again, I was just so blown away at the pace. I mean, as I look at 140 patients accrued over a span of one year, this is something that would take us perhaps three times as long at City of Hope, and that's with a very sort of, what I consider to be large and dedicated kidney cancer program. So, it really underscores, I think, the need for collaboration. And ever since I came back from my visit to you at AIIMS Delhi, I think I've just been sort of transformed in the sense of trying to think of better ways for us to collaborate. One tangible thing that I'm going to get cracking on is seeing whether or not perhaps we can form some partnerships through SWOG or what we call the NCTN, the National Clinical Trials Network here within the U.S. Talk to me about collaboration. I mean, you've been really terrific at this. How do you sort of envision collaboration enhancing the global landscape of oncology? Dr. Atul Batra: That's really amazing, Monty. That's what we need. We have the infrastructure, we have the manpower, we have patients. I mean, these are all high-volume centers. Unfortunately, we are a little less in numbers, so we are more clinically occupied as well. So, sometimes it's kind of tougher, but again, when it comes to helping out the patients, global collaboration, we need to kind of take you guys along with us and have our patients finish trials earlier. This is a win-win situation for patients, one, because they also get exposure or an option to participate in the clinical trials, and second, we can answer all these scientific questions that we have at a much faster pace. All those things can be done within a much shorter span of time for sure. We are so happy to hear that, and with open hands we are ready to collaborate for all these efforts. Dr. Monty Pal: That's awesome. You know, I came back thinking, gosh, this would be so ideal for some of these rare subtypes of kidney cancer. Prospective clinical trials that I'm running in that space where really we're threatened with closure all the time. And if we just sort of extended a hand to, you know, our partners in India and other countries, you know, I'm sure we could get this research done in a meaningful way and that's got to be a win for patients. Atul, I had such a terrific time chatting with you today. I'm looking forward to seeing lots more productivity from your group there. By the way, for our viewership here, take a look and see what AIIMS New Delhi is doing under the leadership of Dr. Batra and others. It is just a real powerhouse and I think that after doing so, you'll be enticed to collaborate as well.  I'm hoping this is the first of many times that we have you on the podcast. Thank you so much for joining. Dr. Atul Batra: Thank you so much for having me here, Monty. It was a pleasure as always speaking to you. And thank you again. Dr. Monty Pal: You got it.  Well, and thanks to our listeners. I encourage you to check out Dr. Batra's paper. We'll actually have a link to the study in the transcript of this episode.  Finally, if you value the insights that you heard today on the ASCO Daily News Podcast, please rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. More on today's speakers:     Dr. Monty Pal   @montypal Dr. Atul Batra @batraatulonc Follow ASCO on social media:          ASCO on X    ASCO on Bluesky         ASCO on Facebook          ASCO on LinkedIn          Disclosures:       Dr. Monty Pal:      Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview     Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical     Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis     Dr. Atul Batra: Stock and Other Ownership Interests: Zydus Pharmaceuticals, Glenmark, Caplin Point Laboratories, Laurus Research Funding: AstraZeneca, Astellas Pharma, Alkem Laboratories

In this week's episode, Blood editor Dr. James Griffin interviews Drs. Paresh Vyas and Andrew Hantel on their research published in this week's issue of Blood. Dr. Vyas discusses his paper, "Rapid clonal selection within early hematopoietic cell compartments presages outcome to ivosidenib combination therapy", which provided new insights as to when and how to intervene to circumvent resistance to AML remission. Dr. Hantel will speak about his paper, "Impact of Modernizing Eligibility Criteria on Enrollment and Representation in AML Clinical Trials". For a real-world cohort of more than 2200 patients with AML, they reported that modernized, safety-based criteria could nearly double trial eligibility, with especially pronounced gains among historically underserved groups.  Both studies highlight how biologic insight and thoughtful trial design can drive more effective, inclusive advances in AML treatment and research. 

In today's episode, recorded in recognition of World Cancer Day, we spoke with Deb Schrag, MD, MPH. Dr Schrag is a medical oncologist at Memorial Sloan Kettering Cancer Center and a nationally recognized leader in cancer outcomes research, health equity, and evidence-based care delivery.In our exclusive interview, Dr Schrag discussed the importance of standardizing high-quality cancer care, addressing inequities in access and outcomes, and how the oncology community can work together to ensure that advances in cancer treatment translate into meaningful benefits for all patients. 

Send us a textMany oncology physical therapists default to studying EVERYTHING when preparing for the ABPTS Oncology Exam. It feels responsible...but this often leads to overstudying, decision fatigue, and unnecessary stress.You'll hear why overstudying is so common, how it undermines your confidence, and why prioritization is a skill that matters more than volume.In this episode, we cover:• Why “studying everything” feels safe but actually backfires• How decision fatigue affects confidence• The difference between responsibility and prioritization• Why clarity beats volume during exam prepLooking for more structure and clarity?I've shared a visual breakdown of this topic in my YouTube playlist for oncology PTs preparing for the ABPTS exam:https://youtube.com/playlist?list=PLZrwPMnzMtblj9rgmUIw7PJCQ8yGJ9IFX&si=-FMqrrcXf9QU2DQ7 Looking for more structure and clarity?If you're preparing for the ABPTS Oncology Specialty Exam and feeling overwhelmed or unsure what to focus on, I've created a short YouTube playlist designed to help you study with more clarity and confidence.These videos walk through prioritization, common pitfalls, and how to think about exam prep more strategically — without Follow TheOncoPT on Instagram.Follow TheOncoPT on LinkedIn.

Send us a textIf you're preparing for the ABPTS Oncology Specialty Exam and feeling overwhelmed or unsure whether you're studying the right things, you're not alone. This stage of exam prep often brings more anxiety — not because you're failing, but because clarity matters more than effort.You'll hear why overwhelm is so common at this point, what actually increases stress during studying, and how clearer prioritization can restore your confidence.In this episode, we cover:• Why overwhelm often peaks late in exam prep• How random studying increases anxiety• The difference between effort and clarity• Why confidence drops without prioritizationLooking for more structure and clarity?If you'd like a more structured, visual walkthrough on this topic, you can watch the full YouTube playlist here:https://youtube.com/playlist?list=PLZrwPMnzMtblj9rgmUIw7PJCQ8yGJ9IFX&si=-FMqrrcXf9QU2DQ7Follow TheOncoPT on Instagram.Follow TheOncoPT on LinkedIn.

Pete Stevenson shares his personal journey with cancer, initially following conventional treatments but later exploring holistic approaches after his oncologists dismissed alternative medicine. Despite skepticism, he attended the Optimum Health Institute in San Diego, where he experienced significant improvements in his health after six weeks. A pivotal moment came when he challenged his self-limiting belief about dying from cancer, realizing there were multiple possible outcomes. This shift in perspective led him to continue experimenting with holistic methods, which he credits with helping him regain his health.Key takeawaysPete Stevenson was diagnosed with stage 4 lymphoma and recovered through a combination of conventional medicine and holistic approachesAfter conventional treatments (chemotherapy, radiation, immunotherapy) failed, Pete found healing through alternative medicine focusing on diet, mental health, stress management, and addressing traumaPete founded Evolve Health to help cancer patients navigate their healing journey with a comprehensive approach covering medical treatment, emotional/mental health, spiritual practice, financial stability, logistics, and community supportThere are numerous resources available for cancer patients including grants, disability benefits, and support services that many patients don't know aboutPete emphasizes that healing requires addressing root causes rather than just symptoms, and that patients have more agency in their healing than they're often toldPete encourages listeners to explore all healing options, trust their bodies, and maintain hope, as recovery from cancer is possible with the right combination of treatments and lifestyle changes. Learn more at evolvvhealth.com and make sure to check out their free resources. Visit ConfidenceThroughHealth.com to find discounts to some of our favorite products.Follow me via All In Health and Wellness on Facebook or Instagram.Find my books on Amazon: No More Sugar Coating: Finding Your Happiness in a Crowded World and Confidence Through Health: Live the Healthy Lifestyle God DesignedProduction credit: Social Media Cowboys

Medical missionaries often feel powerful emotional burden from moral injury, and it is a leading cause of departure from the mission field. But we have learned proven methods of preventing and dealing with moral injury. Use God’s powerful methods to protect yourself and your team, and to grow in wisdom and spirit!

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of insightful updates that highlight the dynamic and rapidly evolving nature of these sectors, driven by scientific advancements, regulatory shifts, and strategic industry maneuvers.Starting with Merck, which is strategically planning for a post-Keytruda era, projecting over $70 billion in annual opportunities over the next decade. With Keytruda's patent expiration looming in 2028, Merck is actively expanding its portfolio through acquisitions and partnerships, focusing on oncology and immunology. These areas have been significantly impacted by Keytruda's success, and Merck's proactive approach aims to sustain growth and innovation beyond its current flagship product. During their 2025 full-year earnings call, CEO Robert Davis emphasized their expansive pipeline, highlighting recent strategic deals as pivotal to Merck's robust pipeline—the broadest it has been in years—signaling long-term growth through diversified therapeutic areas and innovative drug candidates.The U.S. Food and Drug Administration (FDA) is making waves with its regulatory approach to CAR-T cell therapies for autoimmune diseases. This shift reflects an increasing recognition of the potential these therapies hold for transforming treatment paradigms for conditions like lupus and multiple sclerosis. By offering a more flexible regulatory framework, the FDA is encouraging innovation while maintaining a focus on patient safety.In other regulatory news, AstraZeneca faces a setback with the FDA's rejection of its subcutaneous version of Saphnelo for lupus. The decision underscores the challenges associated with developing more patient-friendly administration methods for biologics. However, AstraZeneca remains optimistic about achieving a quick turnaround in the approval process, which could enhance patient adherence by offering a self-administered alternative to intravenous infusions.Sanofi finds itself in the spotlight after CEO Paul Hudson was sanctioned by the UK's Prescription Medicines Code of Practice Authority for making overly ambitious claims about Pfizer's RSV vaccine. This incident illustrates the competitive nature of vaccine procurement and underscores the importance of accurate communication by pharmaceutical leaders.In Massachusetts, Thermo Fisher Scientific is reducing its workforce with the closure of its Franklin site, impacting around 200 employees. This move is part of broader strategic realignments within the industry aimed at optimizing operations and focusing resources on high-growth areas.Acadia Pharmaceuticals faces potential rejection by the European Union for its drug trofinetide intended for Rett syndrome. This highlights ongoing challenges in gaining approval for treatments targeting rare diseases, despite their significant unmet needs.Meanwhile, GSK plans to lay off up to 350 R&D workers across the U.S. and UK as part of efforts to streamline operations and focus on core therapeutic areas. Such layoffs reflect broader industry trends toward consolidation and efficiency amid rising R&D costs.On a more promising note, Pfizer's GLP-1 receptor agonist has demonstrated significant results in a Phase 2b trial for weight loss, validating their substantial investment in this area. The drug's potential to offer competitive weight loss results with monthly dosing positions it as a strong contender in the obesity treatment market. Additionally, Pfizer continues to accelerate its efforts in obesity treatment with promising mid-stage trial results for PF-3944, showing up to a 12.3% weight loss at 28 weeks. This suggests Pfizer is keen on expanding its presence in obesity management through strategic clinical development as competition within this therapeutic area intensifies.The U.S. Department of Health and HumanSupport the show

Bill Thach has had 9 lines of treatment, over 1,000 doses of chemo, and more scans than an airport. He runs ultramarathons for fun. He jokes about being his own Porta Potty. He became a father, then got cancer while his daughter was 5 months old. Today she is 8. He hides the worst of it so she can believe he stands strong, even when he knows that hiding has a cost.We talk about the illusion of strength, what it means to look fine when your body is falling apart, and how a random postcard in an MD Anderson waiting room led him to Man Up to Cancer, where he now leads Diversity and AYA Engagement. Fatherhood. Rage. Sex. Denial. Humor. Survival. All that and why the words good morning can act like a lifeline.RELATED LINKSFight Colorectal CancerCURE TodayINCA AllianceMan Up to CancerWeeViewsYouTubeLinkedInFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This week's episode we are so excited to welcome Dr. Chadi Nabhan, who is a hematologist and medical oncologist, author, and host of Healthcare Unfiltered. We discuss why oncology, our career paths, different career paths in hematology and oncology, contract & negotiation considerations, as well as tips to search for a job.

Three years after finishing treatment for stage 1 breast cancer, Lea learned she had metastatic breast cancer, for which there is no cure today. Even after having to fight for an initial screening, not receiving a recommendation to start tamoxifen and not experiencing transparency from her doctor, Lea Leach kept advocating for herself and making changes be treated as a whole person. Today, she is living her life with purpose and is passionate about advocating for breast cancer awareness, particularly for women of color.

"Radioimmunoconjugates work through a dual mechanism that combines immunologic targeting with localized radiation delivery. The monoclonal antibody components bind to specific tumor-associated antigens such as CD20, expressed on malignant B cells. Once found, the attached radioisotope delivers beta radiation directly to the tumor, causing DNA damage and cell death," Sabrina Enoch, MSN, RN, OCN®, CNMT, NMTCB (CT), theranostics clinical specialist at Highlands Oncology in Rogers, AR, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about radioimmunoconjugates. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.25 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by January 30, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge in the history of, the mechanism of action of, and the use of radioimmunoconjugates in the treatment of cancer. Episode Notes  Complete this evaluation for free NCPD. ONS Podcast™ episodes: Pharmacology 101 series Episode 377: Creating and Implementing Radiopharmaceutical Policies and Procedures Episode 301: Radiation Oncology: Side Effect and Care Coordination Best Practices Episode 298: Radiation Oncology: Nursing's Essential Roles ONS Voice articles: Interprofessional Collaboration Reduces Time to Neutropenia Antibiotic Administration Radiopharmaceuticals and Theranostics Offer New Options for Oncology Nurses to Transform Cancer Care Radiopharmaceuticals Pack a One-Two Punch Against Cancer Safety Is Key in Use of Radiopharmaceuticals Telehealth Has Value During Radiotherapy, Patients Say ONS Voice oncology drug reference sheets: Lutetium Lu 177 dotatate Lutetium Lu 177 vipivotide tetraxetan Radium 223 dichloride Sodium iodide-131 Strontium chloride Sr-89 ONS books: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) Manual for Radiation Oncology Nursing Practice and Education (fifth edition) ONS courses: ONS/ONCC® Chemotherapy Immunotherapy Certificate™ ONS/ONCC® Radiation Therapy Certificate™ Clinical Journal of Oncology Nursing articles: Radiopharmaceutical Safety: Making It Easy Targeted Radionuclide Therapy: A Theranostic Approach to Cancer Therapy ONS Huddle Cards: Radiobiology Radiopharmaceuticals ONS Learning Libraries: Immuno-Oncology Radiation ONS Symptom Interventions for Prevention of Bleeding Drugs@FDA package inserts To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "Radioimmunoconjugates are a specialized subset of radiopharmaceuticals designed to combine the specificity of monoclonal antibodies with the cytotoxic power of radiation. ... Early development focused on B-cell malignancies, particularly non-Hodgkin lymphoma." TS 1:51  "An important concept for nurses to understand is the crossfire effect, where radiation can affect nearby tumor cells, even though not every cell expressed has the target antigen. This helps explain why these agents can be effective even in heterogeneous tumors." TS 3:40 "At present, 90 Y-ibritumomab tiuxetan is the only radioimmunoconjugate approved by the U.S. Food and Drug Administration (FDA) in clinical use. Historically, iodine-131 tositumomab played a major role in establishing these therapy classes, but it's also useful to contrast radioimmunoconjugates with other radiopharmaceuticals, such as iodine-131 therapies, which a lot of places do at this time, used for thyroid diseases, or radium 223, used for metastatic prostate cancer. Unlike those agents, radioimmunoconjugates rely on antibody-mediated targeted rather than physiologic uptake or bone affinity." TS 4:55 "I just try to explain to [patients] that radiation exposure is like being next to a flame. The further you are away, the less heat you get, the less exposure you get. These patients can be radioactive for three days, seven days—it just depends on how fast they excrete it through their bodies with half-life exposure." TS 9:33 "While only one agent is currently approved, the principles established by radioimmunoconjugates continue to guide development for newer targeted radiopharmaceuticals. Emerging agents aim to improve targeting, reduce toxicity, and expand indications beyond hematologic malignancies. This evolution underscores the importance of nursing education in this rapidly changing field." TS 10:41 "Radioimmunoconjugates represent an important bridge between traditional oncology treatments and the future of targeted therapies. Oncology nurses play a vital role in ensuring safe delivery, patient understanding, and collaboration between multidisciplinary teams. So, it's very important to educate and also stay up to date on evidence-based practices." TS 13:12

Shannon Burkett has lived about six lives. Broadway actor. SNL alum. Nurse. Filmmaker. Advocate. Cancer survivor. And the kind of person who makes you question what you've done with your day. She wrote and produced My Vagina—the stop-motion musical kind, not the cry-for-help kind—and built a global movement after her son was poisoned by lead dust in their New York apartment. Out of that came LEAD: How This Story Ends Is Up to Us, a documentary born from rage, science, and maternal defiance. We talked about everything from The Goonies to Patrick Stewart to the quiet rage of parenting in a country that treats public health like a hobby. This episode is about art, anger, resilience, and what happens when an unstoppable theater nerd turned science geek Jersey girl collides with an immovable healthcare system.RELATED LINKSShannon Burkett Official SiteLEAD: How This Story Ends Is Up to UsEnd Lead PoisoningLinkedIn: Shannon BurkettBroadwayWorld ProfileFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Dr. Joyce Ohm is an Associate Professor of Oncology in the Department of Cancer Genetics and Genomics at the Roswell Park Comprehensive Cancer Center. Joyce's research examines the epigenomics involved in development and disease, particularly in cancer. Epigenomics is the study of how your cells package and store the information in your genome. Individual cells within your body package the genome differently to be able to most efficiently use the genes they need. This is important during development, but there are also problems with the epigenome in cancer. In her free time, Joyce enjoys cycling, as well as hiking and kayaking with her two adorable dogs. She was awarded her PhD in Cancer Biology from Vanderbilt University. Afterwards, Joyce conducted postdoctoral research in oncology at Johns Hopkins University School of Medicine. Prior to joining the faculty at Roswell Park, she served on the faculty at the University of North Dakota School of Medicine and Health Sciences. In our interview Joyce tells us more about her life and science.